Yes, patients can absolutely develop methotrexate toxicity despite having normal or even undetectable serum methotrexate levels.
Serum methotrexate levels do not reliably correlate with toxicity, and clinicians must never rely on normal levels to rule out methotrexate toxicity. 1, 2
Key Evidence
The FDA drug label explicitly warns that "toxic effects may be related in frequency and severity to dose or frequency of administration but have been seen at all doses" and can "occur at any time during therapy" 3. This underscores that toxicity is not solely dependent on measurable drug levels.
Direct Case Evidence
A compelling 2024 case report documented a 76-year-old patient who developed severe pancytopenia and bone marrow suppression within 3 weeks of starting low-dose methotrexate (15 mg weekly). Critically, serum methotrexate levels were minimally detectable at only 0.05 umol/L, yet the patient experienced life-threatening toxicity requiring hospitalization 2. Similarly, a 2022 fatal case involved a patient on just 10 mg weekly who developed fatal multiorgan failure despite low-dose therapy 1.
Why This Occurs
Multiple Mechanisms Beyond Serum Levels
Intracellular accumulation: Methotrexate polyglutamates accumulate inside cells and are not reflected in serum measurements 4
Third-space sequestration: The FDA warns that methotrexate exits slowly from pleural effusions or ascites, causing "prolonged terminal plasma half-life and unexpected toxicity" even when serum levels appear normal 3
Tissue-specific sensitivity: Different organs (bone marrow, liver, lungs, kidneys) can develop toxicity independent of systemic drug levels 3
Idiosyncratic reactions: Some patients develop rare, dose-independent toxic responses 5
High-Risk Factors for Toxicity (Even with Normal Levels)
The British Association of Dermatologists guidelines and FDA labeling identify critical risk factors 6, 3:
- Renal impairment (even mild dysfunction in elderly)
- Advanced age (>65 years)
- Lack of folic acid supplementation
- Third-space fluid accumulations (pleural effusions, ascites)
- Drug interactions (NSAIDs, trimethoprim, proton pump inhibitors, penicillins)
- Hypoalbuminemia
- Dehydration
Clinical Management Algorithm
1. Suspect Toxicity Based on Clinical Presentation, NOT Levels
Watch for these warning signs regardless of serum methotrexate levels 6, 3:
- Fever/flu-like illness
- Mouth ulceration or mucositis
- Unexplained bruising or bleeding
- Severe fatigue
- Nausea, vomiting, abdominal pain
- Breathlessness or dry cough
- Pancytopenia on CBC
2. Immediate Action When Toxicity Suspected
Start leucovorin (folinic acid) rescue therapy immediately without waiting for methotrexate levels 1, 2. The 2022 fatal case report explicitly states: "serum levels of MTX do not correlate with toxicity; therefore, folinic acid rescue therapy should be started as soon as MTX toxicity is suspected" 1.
3. Discontinue Methotrexate
Stop the drug immediately when significant toxicity is suspected 3
4. Supportive Care Based on Organ System
- Hematologic: Filgrastim for severe neutropenia, broad-spectrum antibiotics if febrile 2
- Renal: IV hydration, urine alkalinization 3
- GI: High-dose folic acid supplementation 2
Critical Pitfalls to Avoid
Never dismiss clinical signs of toxicity because serum methotrexate levels are normal or low - this is the most dangerous error 1, 2
Don't wait for level results to start leucovorin - begin rescue therapy based on clinical suspicion 1
Remember that elderly patients with "normal" creatinine may have significant renal impairment - use creatinine clearance calculations instead 3
Evacuate third-space fluid before treatment when possible, as this creates a reservoir for delayed toxicity 3
Monitor more frequently in high-risk patients (every 4-8 weeks in NAFLD, elderly, renal impairment) rather than standard 2-3 month intervals 6
The 2025 case of a patient who took methotrexate on two consecutive days (instead of weekly) developed severe pancytopenia and mucosal lesions, demonstrating that even brief dosing errors can cause toxicity independent of steady-state levels 5.